×
Entrez Id:
675
Gene Symbol:
BRCA2
BRCA2
Ovarian Carcinoma
0.500
GeneticVariation
BEFREE
A patient with breast carcinoma diagnosed at the age of 30 years and ovarian carcinoma diagnosed at the age of 41 years was found to have germline mutations in both the BRCA1 and the BRCA2 genes.
9790802
1998
×
Entrez Id:
672
Gene Symbol:
BRCA1
BRCA1
Ovarian Carcinoma
0.500
GeneticVariation
BEFREE
Risk-reducing salpingo-oophorectomy (RRSO) is recommended for BRCA1 /2 mutation carriers because of their increased risk of ovarian carcinoma .
29315498
2018
×
Entrez Id:
672
Gene Symbol:
BRCA1
BRCA1
Ovarian Carcinoma
0.500
GeneticVariation
BEFREE
Women with an existing breast carcinoma diagnosis who are found to carry a BRCA1 /2 mutation have a substantial risk of developing both a contralateral breast carcinoma and ovarian carcinoma .
11900216
2002
×
Entrez Id:
675
Gene Symbol:
BRCA2
BRCA2
Ovarian Carcinoma
0.500
GeneticVariation
BEFREE
BRCA1 and BRCA2 mutation carriers have an 18%-60% and 11%-27% lifetime risk of developing ovarian carcinoma , respectively.
24131970
2013
×
Entrez Id:
7157
Gene Symbol:
TP53
TP53
Ovarian Carcinoma
0.500
AlteredExpression
BEFREE
Studies on the p53 expression and outcome for women with ovarian carcinoma have produced conflicting results.
20629008
2010
×
Entrez Id:
7157
Gene Symbol:
TP53
TP53
Ovarian Carcinoma
0.500
GeneticVariation
BEFREE
These data confirm the findings of previous investigations describing TP53 mutation in ovarian carcinoma and demonstrate that archival paraffin-embedded tissues can be used for such analyses.
9301456
1997
×
Entrez Id:
672
Gene Symbol:
BRCA1
BRCA1
Ovarian Carcinoma
0.500
GeneticVariation
BEFREE
One mutation and three rare variants were identified in four women with no family history of breast or ovarian carcinoma whereas all women with affected first-degree relatives did not harbor BRCA1 mutations.
10951344
2000
×
Entrez Id:
672
Gene Symbol:
BRCA1
BRCA1
Ovarian Carcinoma
0.500
GeneticVariation
BEFREE
Germ-line mutations in the BRCA1 and BRCA2 genes confer a predisposition to breast as well as ovarian carcinoma .
9661879
1998
×
Entrez Id:
672
Gene Symbol:
BRCA1
BRCA1
Ovarian Carcinoma
0.500
GeneticVariation
BEFREE
BRCA1 5382insC mutation in sporadic and familial breast and ovarian carcinoma in Scotland.
9155062
1997
×
Entrez Id:
672
Gene Symbol:
BRCA1
BRCA1
Ovarian Carcinoma
0.500
GeneticVariation
BEFREE
It is not yet known how frequently somatic BRCA1 mutations predispose to breast and ovarian carcinoma in the general female population.
8173065
1993
×
Entrez Id:
672
Gene Symbol:
BRCA1
BRCA1
Ovarian Carcinoma
0.500
GeneticVariation
BEFREE
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.
28882436
2017
×
Entrez Id:
675
Gene Symbol:
BRCA2
BRCA2
Ovarian Carcinoma
0.500
GeneticVariation
BEFREE
Women with family histories suggestive of an increased risk of ovarian carcinoma who have not had a deleterious BRCA1 or BRCA2 mutation identified are commonly suggested to consider ovarian carcinoma screening with transvaginal ultrasound and/or assessment of CA 125 levels.
15948173
2005
×
Entrez Id:
7157
Gene Symbol:
TP53
TP53
Ovarian Carcinoma
0.500
GeneticVariation
BEFREE
Identical p53 mutations were detected in the primary ovarian carcinoma and the subsequent MMMT in each case.
12068173
2002
×
Entrez Id:
7157
Gene Symbol:
TP53
TP53
Ovarian Carcinoma
0.500
GeneticVariation
BEFREE
We conclude that mutation and allelic loss of p53 are common and probably related events in the development of ovarian carcinoma .
7909153
1994
×
Entrez Id:
672
Gene Symbol:
BRCA1
BRCA1
Ovarian Carcinoma
0.500
GeneticVariation
BEFREE
To compare BRCA1 mutations in papillary serous carcinoma of the peritoneum and papillary serous ovarian carcinoma .
9764635
1998
×
Entrez Id:
7157
Gene Symbol:
TP53
TP53
Ovarian Carcinoma
0.500
GeneticVariation
BEFREE
Our NGS study of BM of ovarian carcinoma revealed a significant number of BRCA-mutations beside TP53 , ATM and CHEK2 mutations.
28497333
2017
×
Entrez Id:
675
Gene Symbol:
BRCA2
BRCA2
Ovarian Carcinoma
0.500
Biomarker
BEFREE
Multiple mechanisms cause nearly universal dysfunction of BRCA1 and/or BRCA2 in hereditary and sporadic ovarian carcinoma .
12237285
2002
×
Entrez Id:
7157
Gene Symbol:
TP53
TP53
Ovarian Carcinoma
0.500
Biomarker
BEFREE
Determining p53 mutational status can be useful in predicting therapeutic response to drugs effective in ovarian carcinoma .
11099323
2000
×
Entrez Id:
7157
Gene Symbol:
TP53
TP53
Ovarian Carcinoma
0.500
Biomarker
BEFREE
Recently, this category of ovarian carcinoma has gained increasing attention owing to the recognition of morphological varieties of TP53 -mutated high-grade ovarian carcinoma .
30636633
2019
×
Entrez Id:
675
Gene Symbol:
BRCA2
BRCA2
Ovarian Carcinoma
0.500
GeneticVariation
BEFREE
Prognostic impact of BRCA1 pathogenic and BRCA1/BRCA2 unclassified variant mutations in patients with ovarian carcinoma .
16047333
2005
×
Entrez Id:
675
Gene Symbol:
BRCA2
BRCA2
Ovarian Carcinoma
0.500
GeneticVariation
BEFREE
Orbital metastasis from ovarian carcinoma in a patient with BRCA-2 mutation.
16855505
2006
×
Entrez Id:
672
Gene Symbol:
BRCA1
BRCA1
Ovarian Carcinoma
0.500
Biomarker
BEFREE
Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma .
31653147
2019
×
Entrez Id:
672
Gene Symbol:
BRCA1
BRCA1
Ovarian Carcinoma
0.500
AlteredExpression
BEFREE
Reduced BRCA1 gene expression is common in the sporadic form of ovarian carcinoma .
23339184
2013
×
Entrez Id:
672
Gene Symbol:
BRCA1
BRCA1
Ovarian Carcinoma
0.500
GeneticVariation
BEFREE
Alteration of expression of the tumor suppressor gene BRCA-1 has been widely studied in breast and ovarian carcinoma .
30446260
2019
×
Entrez Id:
672
Gene Symbol:
BRCA1
BRCA1
Ovarian Carcinoma
0.500
GeneticVariation
BEFREE
Eligible patients are premenopausal BRCA1 /2 mutation carriers after completing childbearing without (a history of) ovarian carcinoma .
26286255
2015